Issues related to fertility treatment and coverage for federal employees (no bill); issues related to veteran health care coverage (no bill); H.R. 544, Veterans Infertility Treatment Act (entire bill); S. 2801/H.R. 5492, Veteran Families Health Services Act (entire bill); S. 2386/H.R. 4731, Access to Infertility Treatment and Care Act (entire bill); S. 2213/H.R. 4363, Comprehensive Cancer Survivorship Act (entire bill); S. 1262/H.R. 2828, Family Building FEHB Fairness Act (entire bill); S.2226/H.R. 2670, National Defense Authorization Act (issues related to health care access); H.R. 3838, Preventing Maternal Deaths Reauthorization Act of 2023 (entire bill); H.R. 3305, Black Maternal Health Momnibus Act (entire bill); H.R. 3503, NIH Clinical Trial Diversity Act of 2023 (entire bill).
Duration: May 16, 2016
to
present
General Issues: Health Issues , Veterans
Spending: about $2,318,873 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives, Office of Personnel Management (OPM), White House Office, Veterans Affairs - Dept of (VA), Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Lillian German Counsel, House Judiciary Committee
Democratic Counsel, House Judiciary Committee
Counsel, House Judiciary Committee; Chief of Staff (Reps. E.B. Johnson, Hastings, B. Lee, Jackson-Lee)
Counsel, House Judiciary Committee; Chief of Staff (Reps. Hastings, E.B. Johnson, B. Lee, Jackson-Lee)
Senior Counsel, House Judiciary Committee; Chief of Staff, Rep. E.B. Johnson, Rep. Alcee Hastings, Rep. Sheila Jackson Lee, Rep. Barbara Lee
Deputy Chief Counsel for Oversight and Investigations, House Judiciary Committee; Chief of Staff
Counsel, House Committee on the Judiciary
Tegan Gelfand Professional Staff, House Cmte on Ways & Means; Investigator, Senate Cmte on Judiciary; Research Analyst, Professional Staff, House Cmte on Oversight & Government Reform; Professional Staff, Senate Homeland Security & Governmental Affairs Cmte
Tiffany Shackelford Judicial Staff, Attorney/Judiciary Legislative Correspondent, Office of Senator Bob Menendez
Michael Mawby n/a
Tim Clark n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on April 15.
Original Filing: 301549629.xml
Lobbying Issues
Issues related to fertility treatment and coverage for federal employees (no bill); issues related to veteran health care coverage (no bill); H.R. 544, Veterans Infertility Treatment Act (entire bill); S. 2801/H.R. 5492, Veteran Families Health Services Act (entire bill); S. 2386/H.R. 4731, Access to Infertility Treatment and Care Act (entire bill); S. 2213/H.R. 4363, Comprehensive Cancer Survivorship Act (entire bill); S. 1262/H.R. 2828, Family Building FEHB Fairness Act (entire bill); S.2226/H.R. 2670, National Defense Authorization Act (issues related to health care access); H.R. 3838, Preventing Maternal Deaths Reauthorization Act of 2023 (entire bill); H.R. 3305, Black Maternal Health Momnibus Act (entire bill); H.R. 3503, NIH Clinical Trial Diversity Act of 2023 (entire bill).
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on Jan. 10.
Original Filing: 301523039.xml
Lobbying Issues
Issues related to fertility treatment and coverage for federal employees (no bill); issues related to veteran health care coverage (no bill); H.R. 544, Veterans Infertility Treatment Act (entire bill); S. 2801/H.R. 5492, Veteran Families Health Services Act (entire bill); S. 2386/H.R. 4731, Access to Infertility Treatment and Care Act (entire bill); S. 2213/H.R. 4363, Comprehensive Cancer Survivorship Act (entire bill); S. 1262/H.R. 2828, Family Building FEHB Fairness Act (entire bill); S.2333/H.R. 4420, Pandemic and All Hazards Preparedness Act (issues related to infectious disease); S.2226/H.R. 2670, National Defense Authorization Act (issues related to health care access); H.R. 3838, Preventing Maternal Deaths Reauthorization Act of 2023 (entire bill); H.R.3305, Black Maternal Health Momnibus Act (entire bill); H.R.3503, NIH Clinical Trial Diversity Act of 2023 (entire bill).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Ferring Pharmaceuticals, Inc. lobbied for Ferring Pharmaceuticals . The report was filed on Oct. 19, 2023.
Original Filing: 301508317.xml
Lobbying Issues
H.R. 544, Veterans Infertility Treatment Act (entire bill); S. 2801/H.R. 5492, Veteran Families Health Services Act (entire bill); S. 2386/H.R. 4731, Access to Infertility Treatment and Care Act (entire bill); S. 2213/H.R. 4363, Comprehensive Cancer Survivorship Act (entire bill); S. 1262/H.R. 2828, Family Building FEHB Fairness Act (entire bill); S.2333/H.R. 4420, Pandemic and All Hazards Preparedness Act (issues related to infectious disease and antimicrobial resistance); S.2226/H.R. 2670, National Defense Authorization Act (issues related to health care access); H.R. 3838, Preventing Maternal Deaths Reauthorization Act of 2023 (entire bill); H.R.3305, Black Maternal Health Momnibus Act (entire bill); H.R.3503, NIH Clinical Trial Diversity Act of 2023 (entire bill).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Ferring Pharmaceuticals, Inc. lobbied for Ferring Pharmaceuticals . The report was filed on July 20, 2023.
Original Filing: 301486780.xml
Lobbying Issues
H.R. 4450 and S. 2352, the Access to Infertility Treatment and Care Act (entire bill); H.R. 1957, Veterans Infertility Treatment Act (entire bill); H.R. 2670, the National Defense Authorization Act for Fiscal Year 2024 (issues related to fertility access for the military); Expanding Access to Fertility Care for Servicemembers and Dependents Act (Reintroduction in 118th Congress); Pandemic and All Hazards Preparedness Act (PAHPA) (entire bill; no bill number).
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Ferring Pharmaceuticals, Inc. lobbied for Ferring Pharmaceuticals . The report was filed on April 13, 2023.
Original Filing: 301451190.xml
Lobbying Issues
H.R. 544 Veterans Infertility Treatment Act (whole bill); H.R.6094 Expanding Access to Fertility Care for Servicemembers and Dependents Act (whole bill); H.R. 7845 NIH Clinical Trial Diversity Act (whole bill)
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Ferring Pharmaceuticals, Inc. lobbied for Ferring Pharmaceuticals . The report was filed on Jan. 20, 2023.
Original Filing: 301439200.xml
Lobbying Issues
H.R. 4450 and S. 2352, the Access to Infertility Treatment and Care Act (entire bill); H.R. 1957 Veterans Infertility Treatment Act (entire bill).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Ferring Pharmaceuticals, Inc. lobbied for Ferring Pharmaceuticals . The report was filed on Oct. 19, 2022.
Original Filing: 301410349.xml
Lobbying Issues
Issues related to advancing H.R. 4450 and S. 2352, the Access to Infertility Treatment and Care Act;
Issues related to advancing H.Res. 338, A Resolution Recognizing that Infertility is a widespread problem;
S.Res. 325, A Resolution Recognizing the Seriousness of Polycystic Ovary Syndrome (PCOS);
H.R. 1957 Veterans Infertility Treatment Act;
H.Res. 539, A Resolution Recognizing the Maternal Health Crisis in the United States;
Issues related to mandating Infertility treatment and care for military personnel and military veterans under TriCare.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301396749.xml
Lobbying Issues
Issues related to advancing H.R. 4450 and S.2352, the Access to Infertility Treatment and Care Act
Issues related to advancing H.Res. 338, A Resolution Recognizing that Infertility is a widespread problem....
S.Res. 325, A Resolution recognizing the seriousness of polycystic ovary syndrome (PCOS)
H.R. 1957, Veterans Infertility Treatment Act
Issues related to mandating Infertility treatment and care for military personnel and military veterans under TriCare
H.Res. 539, A Resolution recognizing the maternal health crisis in the United States, and issues related to addressing the maternal health crisis in the United States
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301372490.xml
Lobbying Issues
Issues related to advancing H.R. 4450 and S.2352, the Access to Infertility Treatment and Care Act
Issues related to advancing H.Res. 338, A Resolution Recognizing that Infertility is a widespread problem....
S.Res. 325, A Resolution recognizing the seriousness of polycystic ovary syndrome (PCOS)
H.R. 1957, Veterans Infertility Treatment Act
Issues related to mandating Infertility treatment and care for military personnel and military veterans under TriCare
H.Res. 539, A Resolution recognizing the maternal health crisis in the United States, and issues related to addressing the maternal health crisis in the United States
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on April 19, 2022.
Original Filing: 301361887.xml
Lobbying Issues
Issues related to reporting of average sales price to Medicare, including relevant provisions in Lower Drug Costs Now Act (H.R. 3), Prescription Drug Pricing Reduction Act (S. 2543), Prescription Drug STAR Act (H.R. 2113), Strengthening Average Sales Price Reporting Act (S. 2051), and Consolidated Appropriations Act, 2021 (H.R. 133)
Issues related to advancing Access to Infertility Treatment and Care Act (H.R. 2803, S. 1461)
Issues related to advancing Access to Infertility Treatment for Military Veterans (no bill)
H.R. 1957 - Veterans Infertility Treatment Act of 2021
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1957 - Veterans Infertility Treatment Act and issues related to mandating health coverage for military veterans
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on July 20, 2021.
Original Filing: 301291961.xml
Lobbying Issues
Issues related to reporting of average sales price to Medicare, including relevant provisions in Lower Drug Costs Now Act (H.R. 3), Prescription Drug Pricing Reduction Act (S. 2543), Prescription Drug STAR Act (H.R. 2113), Strengthening Average Sales Price Reporting Act (S. 2051), and Consolidated Appropriations Act, 2021 (H.R. 133)
Issues related to advancing Access to Infertility Treatment and Care Act (H.R. 2803, S. 1461)
Issues related to advancing Access to Infertility Treatment for Military Veterans (no bill)
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on April 21, 2021.
Original Filing: 301268890.xml
Lobbying Issues
Issues related to reporting of average sales price to Medicare, including relevant provisions in Lower Drug Costs Now Act (H.R. 3), Prescription Drug Pricing Reduction Act (S. 2543), Prescription Drug STAR Act (H.R. 2113), Strengthening Average Sales Price Reporting Act (S. 2051), and Consolidated Appropriations Act, 2021 (H.R. 133)
Issues related to advancing Access to Infertility Treatment and Care Act (H.R. 2803, S. 1461)
Issues related to advancing Access to Infertility Treatment for Military Veterans (no bill)
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on April 13, 2021.
Original Filing: 301252068.xml
Lobbying Issues
Issues related to reporting of average sales prices to Medicare, including relevant provisions in the Lower Drug Costs Now Act (H.R. 3), Prescription Drug Pricing Reduction Act (S. 2543), Prescription Drug STAR Act (H.R. 2113), Strengthening Average Sales Price Reporting Act (S. 2051), and Consolidated Appropriations Act, 2021 (H.R. 133)
Reproductive Health legislation including Access to Infertility Treatment and Care Act (S. 1461, H.R. 2803)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on Nov. 20, 2020.
Original Filing: 301227143.xml
Lobbying Issues
S. 2960, H. 5965 - "Access to Infertility Treatment Act." Legislation to require that health plans offered on the group and individual markets, in addition to the FEHB Program, TRICARE and the VA provide coverage for in vitro fertility (IVF)treatments and fertility preservation (FP) for patients who undergo medically necessary procedures that may cause infertility, such as chemotherapy.
House and Senate legislation related to permanently allowing the Department of Veterans Affairs to offer reproductive services to veterans, including in vitro fertilization (IVF) treatments and repeal VA-ban of such services.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on Sept. 1, 2020.
Original Filing: 301206104.xml
Lobbying Issues
S. 2960, H. 5965, "Access to Infertility Treatment Act." Legislation to require that health plans offered on the group and individual markets, in addition to the FEHB Program, TRICARE, and the VA provide coverage for in vitro fertility (IVF) treatments and fertility preservation treatments for patients who undergo medically necessary procedures that may cause infertility, such as chemotherapy.
H.R. 2097, "The Drug Pricing Transparency Act." Pertaining to manufacturer reporting to CMS of the average sales price (ASP) of products reimbursed by Medicare Part B drugs, specifically including products approved by the FDA as medical devices.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on May 18, 2020.
Original Filing: 301183205.xml
Lobbying Issues
S. 2960, H. 5965, "Access to Infertility Treatment Act." Legislation to require that health plans offered on the group and individual markets, in addition to the FEHB Program, TRICARE, and the VA provide coverage for in vitro fertility (IVF) treatments and fertility preservation treatments for patients who undergo medically necessary procedures that may cause infertility, such as chemotherapy.
H.R. 2097, "The Drug Pricing Transparency Act." Pertaining to manufacturer reporting to CMS of the average sales price (ASP) of products reimbursed by Medicare Part B drugs, specifically including products approved by the FDA as medical devices.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on Jan. 27, 2020.
Original Filing: 301130579.xml
Lobbying Issues
S. 2960, H. 5965, "Access to Infertility Treatment Act." Legislation to require that health plans offered on the group and individual markets, in addition to the FEHB Program, TRICARE, and the VA provide coverage for in vitro fertility (IVF) treatments and fertility preservation treatments for patients who undergo medically necessary procedures that may cause infertility, such as chemotherapy.
H.R. 2097, "The Drug Pricing Transparency Act." Pertaining to manufacturer reporting to CMS of the average sales price (ASP) of products reimbursed by Medicare Part B drugs, specifically including products approved by the FDA as medical devices.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on Nov. 7, 2019.
Original Filing: 301081024.xml
Lobbying Issues
S. 2960 - "Access to Infertility Treatment Act." Legislation to require that health plans offered on the group and individual markets, in addition to the Federal Employees Health Benefits Program, TRICARE, and the VA provide coverage for in vitro fertilization (IVF) treatments and fertility preservation treatments for patients who undergo medically necessary procedures that may cause infertility, such as chemotherapy.
FY 2019 Senate Military Construction-VA Appropriations Bill - extending the Dept of Veterans Affairs' authorization allowing the agency to cover fertility services such as in vitro fertilization (IVF) for military service-connected injuries.
H.R. 2087 - the "Drug Pricing Transparency Act:" pertaining to manufacturer reporting to CMS of the average sales price (ASP) of products reimbursed by Medicare Part B drugs, specifically including products approved by the FDA as medical devices.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
Ferring Pharmaceuticals amended a lobbying report for in-house lobbying in Q22019 on July 22, 2019
Original Filing: 301057882.xml
Lobbying Issues
S. 2960, H. 5965 - "Access to Infertility Treatment Care Act:" legislation to require that health plans offered on the group and individual markets, in addition to the Federal Employees Health Benefits Program, TRICARE and the VA provide coverage for in vitro fertility (IVF) treatments and fertility preservation treatments for patients who undergo medically necessary procedures that may cause infertility, such as chemotherapy.
FY 2019 Senate Military Construction-VA Appropriations Bill - extending the Dept of Veterans Affairs' authorization allowing the agency to cover fertility services such as in vitro fertility (IVF) for military service-connected injuries.
H.R. 2087 - the Drug Pricing Transparency Act:" pertaining to manufacturer reporting to CMS of the average sales price (ASP) of products reimbursed by Medicare Part B drugs, specifically including products approved by the FDA as medical devices.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on July 18, 2019.
Original Filing: 301049852.xml
Lobbying Issues
S. 2960, H. 5965 - "Access to Infertility Treatment Care Act:" legislation to require that health plans offered on the group and individual markets, in addition to the Federal Employees Health Benefits Program, TRICARE and the VA provide coverage for in vitro fertility (IVF) treatments and fertility preservation treatments for patients who undergo medically necessary procedures that may cause infertility, such as chemotherapy.
FY 2019 Senate Military Construction-VA Appropriations Bill - extending the Dept of Veterans Affairs' authorization allowing the agency to cover fertility services such as in vitro fertility (IVF) for military service-connected injuries.
H.R. 2087 - the Drug Pricing Transparency Act:" pertaining to manufacturer reporting to CMS of the average sales price (ASP) of products reimbursed by Medicare Part B drugs, specifically including products approved by the FDA as medical devices.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on April 22, 2019.
Original Filing: 301037845.xml
Lobbying Issues
Federal legislation to guarantee insurance coverage of fertility treatments (no bill introduced)
HR 955 / S 319, the Women Veterans and Families Health Services Act of 2019
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on Jan. 21, 2019.
Original Filing: 301011931.xml
Lobbying Issues
H.R. 1318 and S. 1112, End Maternal Deaths Act - enacted into law, Dec. 21, 2018
H. 5965 and S. 2960, Fair Access to Fertility Treatment Act
Proposal to include funding for fertility benefits for Dept. of Veterans Affairs through Senate VA MilCon Appropriations Bill
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on Oct. 22, 2018.
Original Filing: 300994871.xml
Lobbying Issues
H.R. 1318, S. 1112 - Matters relating to maternal mortality legislation
H.R. 5965, S. 2960 - Access to Fertility Treatment and Care Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
Ferring Pharmaceuticals amended a lobbying report for in-house lobbying in Q32018 on Oct. 22, 2018
Original Filing: 300997294.xml
Lobbying Issues
HR 1318, S 1112; issues relating to maternal mortality legislation
HR 5965, S2960, Access to Fertility Treatment and Care Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
Ferring Pharmaceuticals amended a lobbying report for in-house lobbying in Q22018 on Aug. 21, 2018
Original Filing: 300981142.xml
Lobbying Issues
H.R 1318 Preventing Maternal Deaths Act of 2017
S. 1112 Maternal Health Accountability Act of 2017
H.R. 5965, S. 2960 The Access to Infertility Treatment and Care Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on July 19, 2018.
Original Filing: 300972396.xml
Lobbying Issues
H.R 1318 Preventing Maternal Deaths Act of 2017
S. 1112 Maternal Health Accountability Act of 2017
H.R. 5965, S. 2960 The Access to Infertility Treatment and Care Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on April 20, 2018.
Original Filing: 300956242.xml
Lobbying Issues
House and Senate Military Construction and Veterans Affairs and related Agencies Appropriations Act.
Legislation to lift ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans.
Legislation to allow pilot program to provide cryopreservation by Department of Defense.
Legislation to prevent maternal deaths and to identify solutions to improve health care quality and health outcomes for mother (Bill 1112 U.S. Senate/Bill 1318 House of Representatives)
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on Jan. 30, 2018.
Original Filing: 300939079.xml
Lobbying Issues
House and Senate Military Construction and Veterans Affairs and related Agencies Appropriations Act.
Legislation to lift ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans.
Legislation to allow pilot program to provide cryopreservation by Department of Defense.
Legislation to prevent maternal deaths and to identify solutions to improve health care quality and health outcomes for mother.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on Oct. 19, 2017.
Original Filing: 300909202.xml
Lobbying Issues
House and Senate Military Construction and Veterans Affairs and related Agencies Appropriations Act.
Legislation to lift ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans.
Legislation to allow pilot program to provide cryopreservation by Department of Defense.
Legislation to prevent maternal deaths and to identify solutions to improve health care quality and health outcomes for mother.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
Ferring Pharmaceuticals filed a lobbying registration on July 24, 2017 for in-house lobbying efforts, effective July 18, 2017.
Original Filing: 300898362.xml
Issue(s) they said they’d lobby about: House and Senate Military Construction and Veterans Affairs and related Agencies Appropriations Act. Legislation to lift ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans. Legislation to allow pilot program to provide crysopreservation by Department of Defense. .
2nd Quarter, 2017
Ferring Pharmaceuticals amended a lobbying report for in-house lobbying in Q22017 on July 25, 2017
Original Filing: 300898410.xml
Lobbying Issues
House and Senate Military Construction and Veterans Affairs and related Agencies Appropriations Act.
Legislation to lift ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans.
Legislation to allow pilot program to provide cryopreservation by Department of Defense.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on July 19, 2017.
Original Filing: 300890514.xml
Lobbying Issues
House and Senate Military Construction and Veterans Affairs and related Agencies Appropriations Act.
Legislation to lift ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans.
Legislation to allow pilot program to provide cryopreservation by Department of Defense.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
Ferring Pharmaceuticals amended a lobbying report for in-house lobbying in Q12017 on Nov. 1, 2017
Original Filing: 300918533.xml
Lobbying Issues
House and Senate Military Construction and Veterans Affairs and related Agencies Appropriations Act.
Legislation to lift ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans.
Legislation to allow pilot program to provide cryopreservation by Department of Defense.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300874961.xml
Lobbying Issues
House and Senate Military Construction and Veterans Affairs and related Agencies Appropriations Act.
Legislation to lift ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans.
Legislation to allow pilot program to provide cryopreservation by Department of Defense.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on Jan. 6, 2017.
Original Filing: 300844082.xml
Lobbying Issues
House and Senate Military Construction and Veterans Affairs and related agencies Appropriations Act.
Legislation to lift ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans.
Legislation to allow pilot program to provide cryopreservation by Department of Defense
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on Oct. 17, 2016.
Original Filing: 300829176.xml
Lobbying Issues
House and Senate Military Construction and Veterans Affairs and Related Agencies Appropriations Act
Legislation to lift ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans
Legislation to allow pilot program to provide cryopreservation by Department of Defense
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Ferring Pharmaceuticals had in-house lobbyists. The report was filed on July 15, 2016.
Original Filing: 300810583.xml
Lobbying Issues
House and Senate Military Construction and Veterans Affairs and Related Agencies Appropriations Act
Legislation to lift ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans
Legislation to allow pilot program to provide cryopreservation by Department of Defense
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
Ferring Pharmaceuticals filed a lobbying registration on July 14, 2016 for in-house lobbying efforts, effective May 16, 2016.
Original Filing: 300809809.xml
Issue(s) they said they’d lobby about: Legislation to lift the ban on offering in vitro fertilization (IVF) by the Veterans Administration to certain disabled veterans
Legislation related to insurance coverage for in vitro fertilization (IVF) generally .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...